Kailera Therapeutics is a clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for obesity and metabolic disease, with a lead asset (ribupatide) targeting GLP-1/GIP dual agonism. The company completed a record-setting IPO in early June 2026 and presented positive Chinese Phase 2 data at the American Diabetes Association conference, positioning it as a notable China-originated obesity biotech in the public markets.
Company Info
Upcoming Milestones & Key Dates
Global (ex-China) Phase 2/3 ribupatide obesity development update
First post-IPO earnings report and pipeline update
Clinical Development Pipeline
Recent News
Kailera Therapeutics executives said the obesity biotech is back to building pipeline after a record-breaking IPO, presenting Phase 2 data from China on its lead GLP-1/GIP candidate at the American Diabetes Association conference.
Leadership Team
Chief Executive Officer
Careers & Job Openings